J&J Prices $15B in Senior Notes
Ticker: JNJ · Form: 8-K · Filed: May 17, 2024 · CIK: 200406
| Field | Detail |
|---|---|
| Company | Johnson & Johnson (JNJ) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00, $0.01, $22.00, $4.2 billion, $3.6 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, financing, notes
Related Tickers: JNJ
TL;DR
J&J just dropped $15B in new debt across multiple maturities.
AI Summary
On May 17, 2024, Johnson & Johnson filed an 8-K report detailing the issuance of new debt. The company announced the pricing of $15 billion aggregate principal amount of senior unsecured notes. These notes are due in installments ranging from 2024 to 2054, with specific tranches including $1.5 billion due 2024, $2 billion due 2026, $3 billion due 2029, $3.5 billion due 2034, and $5 billion due 2054.
Why It Matters
Johnson & Johnson's issuance of $15 billion in notes indicates its ongoing financing activities and potential use of funds for operations, acquisitions, or debt refinancing.
Risk Assessment
Risk Level: low — This filing is a routine debt issuance announcement and does not contain negative news or significant changes in business operations.
Key Numbers
- $15.0B — Senior Notes Issued (Total principal amount of debt raised by Johnson & Johnson.)
- $1.5B — Notes Due 2024 (Portion of the new debt maturing in the current year.)
- $5.0B — Notes Due 2054 (Longest maturity tranche of the new debt issuance.)
Key Players & Entities
- Johnson & Johnson (company) — Registrant
- $15 billion (dollar_amount) — Aggregate principal amount of senior unsecured notes
- 2024 (date) — Maturity year for a tranche of notes
- 2026 (date) — Maturity year for a tranche of notes
- 2029 (date) — Maturity year for a tranche of notes
- 2034 (date) — Maturity year for a tranche of notes
- 2054 (date) — Maturity year for a tranche of notes
FAQ
What is the total principal amount of the senior unsecured notes issued by Johnson & Johnson?
Johnson & Johnson priced $15 billion aggregate principal amount of senior unsecured notes.
What are the maturity dates for the different tranches of notes issued?
The notes are due in 2024, 2026, 2029, 2034, and 2054.
What is the amount of notes due in 2024?
There is $1.5 billion aggregate principal amount of notes due in 2024.
What is the amount of notes due in 2054?
There is $5 billion aggregate principal amount of notes due in 2054.
What is the purpose of this debt issuance?
The filing does not explicitly state the purpose of the debt issuance, but it is a common financing activity for large corporations.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-17 11:21:36
Key Financial Figures
- $1.00 — ich registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.650% Not
- $0.01 — 4 shares of its common stock, par value $0.01 per share (the "Kenvue Common Stock"),
- $22.00 — ock"), at an initial public offering of $22.00 per share for net proceeds of $4.2 bill
- $4.2 billion — of $22.00 per share for net proceeds of $4.2 billion to the Company. As of the closing of th
- $3.6 billion — . On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercia
Filing Documents
- jnj-20240517.htm (8-K) — 32KB
- 0000200406-24-000053.txt ( ) — 209KB
- jnj-20240517.xsd (EX-101.SCH) — 3KB
- jnj-20240517_def.xml (EX-101.DEF) — 16KB
- jnj-20240517_lab.xml (EX-101.LAB) — 30KB
- jnj-20240517_pre.xml (EX-101.PRE) — 17KB
- jnj-20240517_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events In November 2021, Johnson & Johnson (the "Company") announced its intention to separate its Consumer Health business, creating a new public company (subsequently named Kenvue Inc. ("Kenvue")). On May 8, 2023, Kenvue completed an initial public offering (the "IPO") resulting in the issuance of 198,734,444 shares of its common stock, par value $0.01 per share (the "Kenvue Common Stock"), at an initial public offering of $22.00 per share for net proceeds of $4.2 billion to the Company. As of the closing of the IPO, the Company owned approximately 89.6% of the total outstanding shares of Kenvue Common Stock. On August 23, 2023, the Company completed the disposition of 1,533,830,450 shares of Kenvue Common Stock (representing 80.1% of outstanding Kenvue Common Stock as of August 23, 2023) through an exchange offer, which resulted in the Company acquiring 190,955,436 shares of Johnson & Johnson's common stock in exchange for such shares of Kenvue Common Stock. Following the exchange offer, the Company owned approximately 9.5% of the total outstanding shares of Kenvue Common Stock. On May 15, 2024, the Company issued $3.6 billion aggregate principal amount of commercial paper (the "Commercial Paper") and received $3.6 billion of net cash proceeds to be used for general corporate purposes. On May 17, 2024, the Company completed an exchange (the "Debt-for-Equity Exchange") of its remaining 182,329,550 shares of Kenvue Common Stock for the outstanding Commercial Paper. Upon completion of the Debt-for-Equity Exchange, the Commercial Paper was satisfied and discharged and the Company no longer owns any shares of Kenvue Common Stock.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description of Exhibit 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Johnson & Johnson (Registrant) Date: May 17, 2024 By: /s/ Robert J. Decker, Jr. Robert J. Decker, Jr. Controller (Principal Accounting Officer)